argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026

Markets GlobeNewswire By GlobeNewswire 19 Oct 2026 12:00 1 min read
argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026

October 19, 2026, 8:00 AM ET

Covered in this story

What has happened since

Price move measured from the close nearest publication to the latest quote.

Call it yourself

No calls on $ACR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.

Make the first call on Acres Commercial Realty Corp →
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.com

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.